Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2026-01-24 @ 12:55 PM
Study NCT ID:
NCT05748834
Status:
RECRUITING
Last Update Posted:
2025-01-31
First Post:
2023-02-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Sponsor:
SCRI Development Innovations, LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Breast Cancer | View |
| None | HER2+ | View |
| None | HER2 positive breast cancer | View |
| None | Human epidermal growth factor receptor 2 positive | View |
| None | Doxil | View |
| None | Tucatinib | View |
| None | Tukysa | View |
| None | Anti-HER2 | View |
| None | HER2 inhibitor | View |
| None | HER2 blocker | View |
| None | Tyrosine Kinase Inhibitor | View |
| None | Anthracycline | View |